Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544633 | 0.86 | ALDH1A1 (0.45) | KDM4EALDH1A1HPGDNR3C1SMN1; SMN2 | |
| SCHEMBL19544886 | 0.78 | HPGDS (0.54) | KDM4EALDH1A1HPGDKMT2ANR3C1 | |
| SCHEMBL19544473 | 0.76 | SCN9A (0.51) | KDM4EALDH1A1HPGDRECQLKMT2A | |
| SCHEMBL19533615 | 0.74 | NR3C1 (0.45) | NR3C1SMO | |
| SCHEMBL19544753 | 0.73 | HPGDS (0.46) | KDM4EALDH1A1HPGDRECQLKMT2A | |
| SCHEMBL19544896 | 0.73 | NPSR1 (0.42) | KDM4EALDH1A1HPGDRECQLKMT2A | |
| SCHEMBL25060474 | 0.71 | FNTA (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL19545219 | 0.70 | MAPT (0.47) | KDM4EALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL19544636 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL19544300 | 0.69 | HPGD (0.44) | KDM4EALDH1A1HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | KDM4E 898/4885ALDH1A1 4122/4885HPGD 4511/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | KDM4E 898/4885ALDH1A1 4122/4885HPGD 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.